Introduction to Precision Monitoring in Multiple Sclerosis

Multiple sclerosis management is currently undergoing a significant paradigm shift toward precision medicine. Clinicians increasingly rely on molecular markers, such as serum neurofilament light chain and glial fibrillary acidic protein, to gauge neuroaxonal damage and astrocytic activation. However, the lack of standardized assays often limits the practical application of these indicators in routine care. A recent study has introduced a robust framework utilizing MS biomarker Z-scores to overcome these analytical hurdles. By normalizing values across different platforms, this approach allows for consistent monitoring of patients on ocrelizumab. This methodology provides a much-needed bridge between complex research data and daily clinical decision-making for neurologists. Ultimately, these standardized scores offer a more objective window into the biological response to high-efficacy therapies.

The Challenge of Platform-Agnostic MS Monitoring

Traditional multiple sclerosis monitoring heavily depends on clinical assessment and magnetic resonance imaging. While these tools remain indispensable, they may not always capture subclinical disease activity or neurodegeneration accurately. Serum biomarkers like sNfL and sGFAP offer a window into these biological processes without the need for invasive procedures. Unfortunately, several factors complicate their use in the real world. For example, the concentration values obtained from different platforms, such as Simoa and Elecsys, are often not directly comparable. Furthermore, biological variables like age and body mass index can naturally influence these protein levels. Consequently, a raw concentration value might lead to an incorrect interpretation of a patient's disease state. This lack of standardization has historically hindered the widespread adoption of blood tests in neurology clinics. Without a unified reference system, longitudinal monitoring becomes nearly impossible when laboratory platforms vary between centers. Therefore, addressing this inter-assay variability is essential for developing a truly platform-agnostic framework. By creating a standardized language for biomarker levels, physicians can compare results across different cohorts with higher confidence. This advancement is particularly crucial for evaluating high-efficacy therapies where subtle biological changes are important markers of therapeutic success.

Understanding MS Biomarker Z-Scores and Normalization

The integration of MS biomarker Z-scores represents a significant step toward clinical standardization in neurology. This statistical technique converts raw biomarker concentrations into a standardized score based on a healthy reference population. Most importantly, these scores adjust for confounding factors such as age and body mass index, which increase sNfL and sGFAP levels physiologically. By using covariate-adjusted Z-scores, researchers can harmonize data from different assay platforms. This normalization ensures that a Z-score of 2.0 indicates the same degree of deviation from normal, regardless of the test platform. Notably, this framework allows for a more accurate comparison of longitudinal trajectories in individual patients. Instead of looking at shifting absolute numbers, clinicians can track how a patient’s score moves relative to a normative baseline. This method effectively filters out the noise created by platform differences and individual biological traits. For patients starting ocrelizumab, having a standardized baseline score is vital. It enables the care team to see if the therapy successfully moves the patient back toward a biological low-risk zone. Furthermore, the use of Z-scores facilitates multicenter collaborations, as data from various sources can be pooled without losing statistical integrity or clinical relevance.

Differential Trajectories in Relapsing and Progressive MS

Research focusing on patients treated with ocrelizumab has revealed distinct biomarker profiles based on the specific type of multiple sclerosis. At the start of therapy, individuals with relapsing MS typically exhibit higher sNfL Z-scores compared to those with primary progressive MS. This elevation likely reflects the higher level of acute inflammatory activity and focal neuroaxonal damage seen in relapsing forms. However, once ocrelizumab therapy begins, these sNfL levels usually show a marked and rapid decline. In contrast, sGFAP Z-scores often remain more stable during the early phases of treatment. For patients with progressive disease, the biomarker profile tends to be more consistent over time. This suggests a different underlying pathological drive that is less influenced by acute B-cell depletion. Interestingly, patients with relapsing MS who show concurrent elevation of both sNfL and sGFAP at baseline often sustain higher biomarker levels throughout the first two years. This specific subgroup appears to diverge significantly from the more stable profile of progressive patients. These findings suggest that baseline biomarker stratification could help identify patients who might require more intensive monitoring or earlier adjustments to their management plan. Understanding these divergent trajectories allows for a more personalized approach to long-term care in the ocrelizumab era.

Predicting Treatment Failure with the 12-Month Threshold

Identifying which patients are not responding optimally to therapy is a critical goal for neurologists worldwide. Recent evidence highlights that the 12-month mark is a pivotal window for biological assessment. Specifically, failing to achieve a significant relative reduction in biomarker levels at this timepoint serves as a strong prognostic indicator. Researchers found that a relative Z-score reduction of 50% or more by month 12 acts as a practical threshold for distinguishing responders. Patients who fail to reach this target for sNfL are over seven times more likely to have persistently elevated levels at 24 months. Even more dramatically, the risk for persistent sGFAP elevation is 32 times higher in those who do not meet the 50% reduction threshold. This 12-month assessment outperformed both baseline measurements and 6-month checks in terms of predictive accuracy. Therefore, the one-year follow-up provides the most reliable snapshot of a patient's long-term biological trajectory under ocrelizumab. By applying this reduction rule, clinicians can identify exploratory non-responders much earlier than traditional clinical or imaging markers might allow. This early detection is vital for preventing the accumulation of irreversible neurological damage. Consequently, the 12-month biomarker check-up should be considered a cornerstone of modern therapeutic monitoring protocols.

Implementing Biomarker Surveillance in Clinical Practice

The ability to use platform-agnostic Z-scores simplifies the logistics of biomarker monitoring in busy clinical settings. Because the scores are harmonized, neurologists can confidently interpret results coming from different diagnostic laboratories. This flexibility is particularly important for patients who travel for specialized care or those in regions with inconsistent laboratory access. When a patient shows persistent biomarker elevation despite high-efficacy therapy, it signals a need for closer clinical surveillance. This might involve more frequent MRI scans or a more detailed assessment for progression independent of relapse activity. While ocrelizumab is highly effective, the biomarker data suggests that a subset of patients may still harbor smoldering inflammation. Specifically, the stability of sGFAP in many patients highlights the continued need for therapies that target astrocytic activation more directly. In addition to monitoring current treatment, these Z-score trajectories provide valuable baseline data for future clinical decisions. If a patient eventually needs to switch therapies, having a clear record of their biological response is invaluable. Furthermore, sharing these results with patients can improve treatment adherence by providing objective proof of therapeutic benefit. Ultimately, integrating these molecular insights into routine practice empowers both doctors and patients to make more informed choices about their long-term health.

Frequently Asked Questions

What are MS biomarker Z-scores?

MS biomarker Z-scores are standardized values that represent how far a patient’s biomarker levels deviate from a healthy reference population. These scores are crucial because they adjust for age and body mass index, allowing clinicians to interpret results accurately regardless of the specific laboratory platform or assay used for the test.

Why is the 12-month mark critical for monitoring?

The 12-month timepoint is the most reliable predictor of long-term biomarker status in patients on ocrelizumab. Specifically, failing to achieve a 50% reduction in Z-scores by one year strongly indicates that biomarker levels will remain elevated at 24 months, suggesting a high risk of ongoing subclinical disease activity.

How do sNfL and sGFAP differ in MS monitoring?

Serum NfL primarily reflects acute neuroaxonal injury and usually drops quickly after starting effective therapy in relapsing MS. In contrast, sGFAP is a marker of astrocytic activation and neurodegeneration. It tends to remain more stable or decrease more slowly, providing a different perspective on chronic disease progression and smoldering inflammation.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Inojosa H et al. From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosis. J Neurol. 2026 Jul 10. doi: 10.1007/s00415-026-13986-9. PMID: 42429990.

Kuhle J, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Lancet Neurol. 2024;23(3):305-316.

Abdelhak A, et al. Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) in Multiple Sclerosis: Distinct biological processes. Brain. 2025;148(2):542-555.